Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.

Danish drugmaker Novo Nordisk said Wednesday that effective immediately it will drop the price for all doses of Wegovy to $499, down from $650.

Novo said the new pricing is available to both the uninsured and people who have insurance that doesn’t cover the weight-loss drugs.

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.

Patients start taking the injectable drugs at smaller dose levels and then increase the amount over time. — Associated Press